Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL)

References

• Gruss H J, Pinto A, Duyster J, Poppema S, Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunology Today 1997; 18: 156–163
   PubMedGoogle Scholar
• Diehl V, Thomas R K, Re D. Part II: Hodgkin's lymphoma diagnosis and treatment. Lancet Oncology 2004; 5: 19–26
   PubMed Web of Science ®Google Scholar
• Wagstaff J, Steward W, Jones M, Deakin D, Todd I, Wilkinson P, et al. Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP. Hematology & Oncology 1986; 4: 135–147
   PubMed Web of Science ®Google Scholar
• Folkman J, D'Amore P A. Blood vessel formation: what is its molecular basis?. Cell 1996; 87: 1153–1155
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumour angiogenesis. The molecular basis of cancer, J Mendelsson, P M Howely, M A Israel, L A Liotta. WB Saunders, Philadelphia 1995; 206–235
   Google Scholar
• Mangi M H, Newland A C. Angiogenesis and angiogenic mediators in haematological malignancies. British Journal of Haematology 2000; 111: 43–51
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Annals of Hematology 2000; 79: 574–577
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Marzullo A, Nico B, Ria R, Roncali L, Dammacco F. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. International Journal of Cancer 2000; 85: 171–175
   PubMed Web of Science ®Google Scholar
• Molica S, Vacca A, Ribatti D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002; 100: 3344–3351
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Gribabis D A, Kavantzas N, Angelopoulou M K, et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia 2005; 19: 894–900
   PubMed Web of Science ®Google Scholar
• Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712–3718
   PubMed Web of Science ®Google Scholar
• Molica S, Vitelli G, Levato D, Ricciotti A, Digiesi G. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. British Journal of Cancer 2002; 86: 31–35
   PubMed Web of Science ®Google Scholar
• Koukourakis M I, Giatromanolaki A, O'Byrne K J, Comley M, Whitehouse R M, Talbot D C, et al. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. British Journal of Cancer 1997; 75: 477–481
   PubMed Web of Science ®Google Scholar
• Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Research Treatment 1995; 36: 193–204
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemöller K, Jacob C, Zavriski I, Heider U, Euker J, et al. Increased bone marrow angiogenesis is of prognostic relevance in patients with chronic lymphocytic leukaemia. Blood 2001; 98, Abstract no 1521
   Web of Science ®Google Scholar
• Talks K L, Harris A L. Current status of antiangiogenic factors. British Journal of Haematology 2000; 109: 477–489
   PubMed Web of Science ®Google Scholar
• Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003; 102: 2763–2767
   PubMed Web of Science ®Google Scholar
• Steins M B, Padro T, Bieker R, Ruis S, Kropff M, Kienast J, et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002; 99: 834–839
   PubMed Web of Science ®Google Scholar
• Freeman M R, Schneck F X, Gagnon M L, Corless C, Soker S, Niknejad K, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Research 1995; 55: 4140–4145
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Gomez D E, Shibuya M, Thorgeirsson U P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Research 1996; 56: 2013–2016
   PubMed Web of Science ®Google Scholar
• Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda M, Hayashi Y, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clinical Cancer Research 1996; 2: 1411–1416
   PubMed Web of Science ®Google Scholar
• Bellamy W T, Richter L, Frutiger Y, Grogan T M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Research 1999; 59: 728–733
   PubMed Web of Science ®Google Scholar
• Foss H D, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. Journal of Pathology 1997; 183: 44–50
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostopoulou I A, Talks K L, Turley H, Debnam P, Tan D C, Mariatos G, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. Journal of Pathology 2002; 197: 677–683
   PubMed Web of Science ®Google Scholar
• Agarwal B, Naresh K N. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. Journal of Pathology 2003; 201: 334–335, Re: Doussis-Anagnostopoulou et al.
   PubMed Web of Science ®Google Scholar
• List A F. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist 2001; 6(Suppl 5)24–31
   PubMed Web of Science ®Google Scholar
• Moghaddam A, Bicknell R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 1992; 31: 12141–12146
   PubMed Web of Science ®Google Scholar
• Moghaddam A, Zhang H T, Fan T P, Hu D E, Lees V C, Turley H, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proceedings of the National Academy of Sciences (USA) 1995; 92: 998–1002
   PubMed Web of Science ®Google Scholar
• Engels K, Fox S B, Whitehouse R M, Gatter K C, Harris A L. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. Journal of Pathology 1997; 182: 414–420
   PubMed Web of Science ®Google Scholar
• Vermeulen P B, Gasparini G, Fox S B, Toi M, Martin L, McCulloch P, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. European Journal of Cancer 1996; 32A: 2474–2484
   PubMed Web of Science ®Google Scholar
• Zhang X, Yamashita M, Uetsuki H, Kakehi Y. Angiogenesis in renal cell carcinoma: evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. International Journal of Urology 2002; 9: 509–514
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Gribabis D A, Kavantzas N, Angelopoulou M K, Siakantans M P, Patsouris E. A morphometric study of bone marrow angiogenesis in hairy cell leukaemia with clinicopathological correlations. British Journal of Haematology 2003; 122: 900–910
   PubMed Web of Science ®Google Scholar
• Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637–2644
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis and tissue factor. Natural Medicine 1996; 2: 1671–1668
   Web of Science ®Google Scholar
• Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig N E. Halting angiogenesis suppresses carcinoma cell invasion. Natural Medicine 1997; 3: 1222–1227
   PubMed Web of Science ®Google Scholar
• Niemoller K, Jakob C, Heider U, Zavrski I, Eucker J, Kaufmann O, et al. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II – III. Journal of Cancer Research, Clinical Oncology 2003; 129: 234–238
   PubMed Web of Science ®Google Scholar
• Senger D R, Galli S J, Dvorak A M, Perruzzi C A, Harvey V S. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983–985
   PubMed Web of Science ®Google Scholar
• Plate K H, Breier G, Weich H A, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845–848
   PubMed Web of Science ®Google Scholar
• Rak J, Filmus J, Kerbel R S. Reciprocal paracrine interactions between tumour cells and endothelial cells: the ‘angiogenesis progression’ hypothesis. European Journal of Cancer 1996; 32A: 2438–2450
   PubMed Web of Science ®Google Scholar
• Chen H, Treweeke A T, West D C, Till K J, Cawley J C, Zuzel M, Toh C H. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000; 96: 3181–3187
   PubMed Web of Science ®Google Scholar
• Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630–2636
   PubMed Web of Science ®Google Scholar
• Boocock C A, Charnock Jones D S, Sharkey A M, McLaren J, Barker P J, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. Journal of the National Cancer Institute 1995; 87: 506–516
   PubMed Web of Science ®Google Scholar
• Kojima H, Shijubo N, Abe S. Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma. Cancer 2002; 94: 1083–1093
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Kuwazuru Y, Furukawa T, Yoshida H, Yamada K, Akiyama S. Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochimica et Biophysica Acta 1990; 1034: 107–113
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostopoulou I A, Remadi S, Turley H, Gindre P, Comley M, Borisch B, Gatter K C. Platelet-derived endothelial cell growth factor/thymidine phosphorylase immunohistochemical expression in lymphoid tissue and lymphoid malignancies. Human Pathology 1997; 28: 1146–1151
   PubMed Web of Science ®Google Scholar
• Li G, Kawakami S, Kageyama Y, Yan C, Saito K, Kihara K. IFN gamma-induced up-regulation of PD-ECGF/TP enhances the cytotoxicity of 5-fluorouracil and 5′-deoxy-5-fluorouridine in bladder cancer cells. Anticancer Research 2002; 22: 2607–2612
   PubMed Web of Science ®Google Scholar
• Zhu G H, Lenzi M, Schwartz E L. The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells. Oncogene 2002; 21: 8477–8485
   PubMed Web of Science ®Google Scholar
• Schwartz E L, Baptiste N, Megati S, Walder S, Otter B A. 5-Ethoxy-2′-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression. Cancer Research 1995; 55: 3543–3550
   PubMed Web of Science ®Google Scholar
• Voronov E, Shouval D S, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proceedings of the National Academy of Sciences (USA) 2003; 100: 2645–2650
   PubMed Web of Science ®Google Scholar
• Giraud E, Primo L, Audero E, Gerber H P, Koolwijk P, Soker S, et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. Journal of Biological Chemistry 1998; 273: 22128–22135
   PubMed Web of Science ®Google Scholar
• Breier G, Blum S, Peli J, Groot M, Wild C, Risau W, Reichmann E. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. International Journal of Cancer 2002; 97: 142–148
   PubMed Web of Science ®Google Scholar